Clinical Trials Logo
  1. Home
  2. Retinal Vein Occlusion
  3. NCT05532475
  4. Details
NCT05532475 Clinical Trial

Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

Retinal Vein Occlusion Clinical Trial

Official title:
Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05532475
Other study ID # MS-654-2021
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 12, 2022
Est. completion date October 2022

Study information
Verified date September 2022
Source Kasr El Aini Hospital
Contact Mohamed A Attya, M.D.
Phone +201113332892
Email mohamed.attya86@cu.edu.eg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Recruitment information / eligibility
Status Recruiting
Enrollment 40
Est. completion date October 2022
Est. primary completion date October 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection Exclusion Criteria: 1. Diabetic patients. 2. Other causes of retinal vascular diseases. 3. Patients with history of treatment of retinal vein occlusion. 4. Previous intraocular surgery except cataract surgery performed 6 months before the study. 5. Subjects with severe systemic inflammatory diseases 6. Retinal vein occlusion secondary to retinal vasculitis. 7. All retinal pathologies. 8. Patients receiving Systemic steroids or Immunosuppressive therapy.

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• measurement of vitreous level of tumor necrosis factor alpha
measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

Locations
Country Name City State
Egypt Kasr ALainy University hospital Cairo

Sponsors (1)
Lead Sponsor Collaborator
Kasr El Aini Hospital

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary to assess vitreous level of tumor necrosis factor alpha in retinal vein occlusion and compare it to patient undergoing cataract surgery single measurement
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT04592419 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 3
Recruiting NCT05133791 - NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients Phase 1
Withdrawn NCT04011358 - Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study N/A
Completed NCT02898480 - Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning N/A
Recruiting NCT01581151 - Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion N/A
Completed NCT01428388 - Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion N/A
Completed NCT00970957 - Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Phase 3
Recruiting NCT04075695 - Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
Recruiting NCT03525132 - Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) N/A
Recruiting NCT03762226 - Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study
Recruiting NCT02257333 - Retinal Thrombosis and Atherosclerosis
Recruiting NCT04140448 - Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
Active, not recruiting NCT05003258 - Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection N/A
Terminated NCT04707625 - Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment Phase 4
Recruiting NCT04142164 - Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections N/A
Completed NCT02523339 - Study of Retinal Oxygenation in Central Retinal Vein Occlusion
Active, not recruiting NCT01449682 - Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections. Phase 3
Completed NCT01568021 - Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO) N/A
Terminated NCT01225146 - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2) Phase 1